Recursion Pharmaceuticals, Inc. (RXRX) Tops Q3 EPS by 1c

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q3 EPS of ($0.36), $0.01 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $5.18 million versus the consensus estimate of $16.95 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.

You May Also Be Interested In

• Comcast (CMCSA) Falls Following Comments at Goldman Sachs Conf, Down 4%
• Raymond James comments on Fair Isaac (FICO): 'we think the most likely outcome is that FICO will maintain ~100% market share in this environment'
• Opus Genetics (IRD) PT Raised to $17 at Citizens